Small Cell Lung Cancer | Clinical

PARP Inhibitor Regimen Leads to Promising ORR in ES-SCLC

August 08, 2022

The combination of talazoparib and temozolomide elicited an objective response rate of 39.3% in patients with extensive-stage small cell lung cancer who were relapsed or refractory to a frontline platinum-based chemotherapy regimen, according to data from a phase 2 UCLA/TRIO-US L-07 trial.

Roundtable Discussion: Mohamed Analyzes Data for Understanding ES-SCLC Treatment

July 18, 2022

During a Targeted Oncology case-based roundtable event, Mohamed K. Mohamed, MD, PhD, discussed with participants the challenges of treating extensive-stage small cell lung cancer and their views of the CASPIAN and IMpower 133 trial results.